CA
RCUS icon

Continuum Advisory’s Arcus Biosciences RCUS Stock Holding History

Continuum Advisory’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-33
Closed -$259 – 1303
2025
Q1 		$259 Hold
33
– – ﹤0.01% 1617
2024
Q4 		$491 Hold
33
– – ﹤0.01% 1736
2024
Q3 		$520 Hold
33
– – ﹤0.01% 1779
2024
Q2 		$503 Hold
33
– – ﹤0.01% 1597
2024
Q1 		$533 Buy
+33
New +$571 ﹤0.01% 1593

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Continuum Advisory's RCUS Position: Q2 2025 in Review

Continuum Advisory sold out of Arcus Biosciences (RCUS) in Q2 2025, closing a stake of 33 shares — an estimated $259 sold.

Continuum Advisory first reported a position in RCUS in Q1 2024 and held it in 5 quarters. The position peaked at $533 in Q1 2024. 185 funds tracked by Wall St. Rank hold RCUS as of Q2 2025.

  • Continuum Advisory reported no remaining Arcus Biosciences position as of Q2 2025 after selling out during the quarter.
  • Continuum Advisory sold 33 Arcus Biosciences shares in Q2 2025, an estimated $259.
  • Continuum Advisory first reported a position in Arcus Biosciences in Q1 2024 and held it in 5 quarters.
  • Continuum Advisory's Arcus Biosciences position peaked at $533 in Q1 2024.
  • 185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.